Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart valve patients may go home sooner: new study reveals key factors

NCT ID NCT02956915

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 300 patients with severe aortic stenosis who had a minimally invasive heart valve replacement (TAVI) to see how long they stayed in the hospital and why some stayed longer than 3 days. The goal was to find out what factors, like needing a blood transfusion or a pacemaker, lead to longer hospital stays. The results could help doctors plan earlier discharge for suitable patients, saving costs and reducing hospital time for elderly and frail individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

May 2017

Finished

Feb 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stable patients with severe symptomatic aortic stenosis * Patient undergoing planned TF-TAVI with the SAPIEN-3 prosthesis, * TF-TAVI using a minimalist approach of local anesthesia and conscious sedation Exclusion Criteria: * The use of other (than Edwards SAPIEN-3 or XT) transcatheter aortic valve devices. * TF-TAVI requiring general anesthesia or surgical cut-down. * TF-TAVI performed in unstable patients or on an urgent/emergent basis. * Non-transfemoral routes of valve delivery (eg. transapical, transaortic, etc). * Discharge back home impossible (including transfer in another hospital) * Programmed transfer to another hospital

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe symptomatic aortic stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe symptomatic aortic stenosis

Contacts and locations

Locations

  • AP-HP Bichat - Claude Bernard Hospital

    Paris, France

  • Brest University Hospital

    Brest, France

  • Jacques Cartier Private Hospital

    Massy, France

  • Rennes University Hospital

    Rennes, France

  • Rouen University Hospital

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.